Content overview: “Moderna’s mRNA Cancer Vaccine Faces Real Test: Long-Term Recurrence Prevention, Not Just B”. The first Phase 3 data for Moderna’s investigational cancer vaccine, mRNA-4157 (V940), in combination with Merck’s Keytruda, has sparked debate about its role in treating high-risk melanoma. While the combination showed a statistically significant improvement in recurrence-free survival compared to Keytruda alone, the absolute benefit was modest, leading some experts to question whether the added complexity and cost are justified. The real test, however, may not be about outperforming Keytruda in the short term, but about preventing cancer from returning years later.
Melanoma is notorious for late recurrences, and a vaccine that trains the immune system to recognize and destroy residual cancer cells could offer durable protection that checkpoint inhibitors alone cannot. Moderna and Merck are continuing to follow patients to assess long-term outcomes, and the vaccine’s ultimate value may hinge on whether it can keep cancer at bay for a decade or more. For the complete material, the listing points back to the source inside the network.